VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. The announcement came as Xlife Sciences AG, a Swiss incubator and accelerator, reported operational and scientific progress across its portfolio during the first half of 2026.
Xlife Sciences said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy. The portfolio comprises 416 patents and patent applications, including 216 granted intellectual property rights. Xlife Sciences is focused on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For the second half of 2026, Xlife Sciences said it will continue supporting VERAXA in establishing industry partnerships while pursuing commercialization and further development across its portfolio. Xlife Sciences also reported progress at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma during the first half of 2026.
The news matters because it signals VERAXA's transition from a private biotech to a publicly traded company with a clear strategic focus on oncology. The completion of its business combination and Nasdaq listing provides the company with a financing base to advance its pipeline, which could lead to new treatments for cancer patients. The industrial partnerships could accelerate the commercialization of its technology platforms, potentially bringing innovative therapies to market faster.
For investors, the progress at Xlife Sciences' portfolio companies, including VERAXA, may indicate a maturing pipeline with multiple shots on goal. The 416 patents and patent applications, including 216 granted IP rights, underscore the depth of the portfolio and its potential for future value creation. The full report is available at https://ibn.fm/LwLwP.
Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. More information is available at www.xlifesciences.ch.
VERAXA's focus on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, positions it in a competitive but promising area of oncology research. The company's BiTAC format is a registered trademark of VERAXA Biotech GmbH. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
As VERAXA advances its pipeline, the implications for the oncology field could be significant. Bispecific antibodies and ADCs are among the most active areas of cancer drug development, and successful clinical progress could offer new options for patients with high unmet needs. The support from Xlife Sciences, with its emphasis on bridging research and development to healthcare markets, may help VERAXA navigate the complex path to commercialization.
The announcement was originally distributed by NEWMEDIAWIRE. Forward-looking statements in the release note risks and uncertainties that could cause actual results to differ materially from expectations.
